This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Merck Sharp & Dohme LLC. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Cheng Wang: Innovator in Selective Cytotoxic Agents
Introduction
Cheng Wang is a notable inventor based in Fort Washington, PA (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of selective cytotoxic agents. With a total of 2 patents, his work focuses on innovative solutions for treating HIV and related conditions.
Latest Patents
Cheng Wang's latest patents include the development of tetrahydroquinazoline derivatives as selective cytotoxic agents. These derivatives are designed to selectively kill HIV-infected GAG-POL expressing cells while minimizing cytotoxicity to HIV-naïve cells. This innovation holds promise for the treatment and prophylaxis of HIV infection, as well as for delaying the onset or progression of AIDS or AIDS Related Complex (ARC).
Career Highlights
Cheng Wang is currently employed at Merck Sharp & Dohme LLC, where he continues to advance his research in the pharmaceutical industry. His work is characterized by a commitment to improving therapeutic options for patients affected by HIV.
Collaborations
Cheng collaborates with esteemed colleagues, including Antonella Converso and David N Hunter, to further enhance the impact of his research and innovations.
Conclusion
Cheng Wang's contributions to the field of selective cytotoxic agents represent a significant advancement in the fight against HIV and related diseases. His innovative work at Merck Sharp & Dohme LLC continues to pave the way for new therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile